Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor - Vande Casteele, Niels; Abreu, Maria T.; Flier, Sarah; Papamichael, Konstantinos; Rieder, Florian; Silverberg, Mark S.; Khanna, Reena; Okada, Lauren; Yang, Lei; Jain, Anjali; Cheifetz, Adam S. (Clinical gastroenterology and hepatology, 2022)
Keywords: Adalimumab - therapeutic use; Autoantibodies; Drug Monitoring; Gastroenterology and Hepatology; Genome-Wide Association Study; Humans; Inflammatory Bowel Diseases - drug therapy; Infliximab - therapeutic use; Tumor Necrosis Factor Inhibitors - therapeutic use